Abstract
The potential of human glucagon-like peptide-1 (hGLP-1) as a therapeutic agent is limited by its high aggregation propensity. We show that hGLP-1 forms amyloid-like structures that are preceded by cytotoxic aggregates, suggesting that aggregation of biopharmaceuticals could present a cytotoxic risk to patients besides the reported increased risk in immunogenicity.
Keywords: hGLP-1, protein aggregation, biopharmaceuticals, diabetes, amyloid fibrils, Alzheimer's disease
Protein & Peptide Letters
Title: Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1)
Volume: 16 Issue: 12
Author(s): S. Poon, N. R. Birkett, S. B. Fowler, B. F. Luisi, C. M. Dobson and J. Zurdo
Affiliation:
Keywords: hGLP-1, protein aggregation, biopharmaceuticals, diabetes, amyloid fibrils, Alzheimer's disease
Abstract: The potential of human glucagon-like peptide-1 (hGLP-1) as a therapeutic agent is limited by its high aggregation propensity. We show that hGLP-1 forms amyloid-like structures that are preceded by cytotoxic aggregates, suggesting that aggregation of biopharmaceuticals could present a cytotoxic risk to patients besides the reported increased risk in immunogenicity.
Export Options
About this article
Cite this article as:
Poon S., Birkett R. N., Fowler B. S., Luisi F. B., Dobson M. C. and Zurdo J., Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1), Protein & Peptide Letters 2009; 16 (12) . https://dx.doi.org/10.2174/092986609789839232
DOI https://dx.doi.org/10.2174/092986609789839232 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antitumoral Potential of Snake Venom Phospholipases A2 and Synthetic Peptides
Current Pharmaceutical Biotechnology The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology mGlu5, Dopamine D<sub>2</sub> and Adenosine A<sub>2A</sub> Receptors in L-DOPA-induced Dyskinesias
Current Neuropharmacology Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications
Current Drug Targets A Review on Extraction, Synthesis and Anticancer Activity of Betulinic Acid
Current Bioactive Compounds Immunotoxins and Other Conjugates: Pre-clinical Studies
Mini-Reviews in Medicinal Chemistry GPER and ER: Estrogen Receptors with Distinct Biological Roles in Breast Cancer
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry <i>Piper sarmentosum</i> Roxb. Attenuates Beta Amyloid (Aβ)-Induced Neurotoxicity <i>Via</i> the Inhibition of Amyloidogenesis and Tau Hyperphosphorylation in SH-SY5Y Cells
Current Alzheimer Research Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Current Drug Targets Inhibition of Key Fungal (02) Protein(s) (Aspergillus fumigatus) In-Response to Treatment with Poly-Acid Ligand
Current Proteomics Computational Elucidation of Phylogenetic, Functional and Structural Features of Methioninase from <i>Pseudomonas, Escherichia, Clostridium</i> and <i>Citrobacter Strains</i>
Recent Patents on Biotechnology CNS Immune Surveillance and Neuroinflammation: Endocannabinoids Keep Control
Current Pharmaceutical Design Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Targeting Autophagy in the Brain: A Promising Approach?
Central Nervous System Agents in Medicinal Chemistry Antiinflammatory Activity of Melatonin in Central Nervous System
Current Neuropharmacology Clearance of Genetic Variants of Amyloid β Peptide by Neuronal and Non-neuronal Cells
Protein & Peptide Letters Provoking Neuroprotection by Peroxynitrite
Current Pharmaceutical Design Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry